Plasmodium vivax: Comparison of the immune responses between oral and parenteral immunization of rPv54 in BALB/c mice

• Published in: Experimental parasitology 2010-10, Vol.126 (2), p.217-223
• Main Authors: Kwon, Myoung-Hee, Kim, Hyung-Hwan, Lee, Ho-Sa, Kim, Tong-Soo, Oh, Chang-Mi, Ahn, Yong-Joo, Hwang, Seo-Kyong, Sohn, Youngjoo, Kim, Hyuck, Lee, Hyeong-Woo
• Format: Article
• Language: English
• Subjects: Administration, Oral; Animals; Antibodies, Protozoan - biosynthesis; Biological and medical sciences; Escherichia coli; Female; Fundamental and applied biological sciences. Psychology; Humans; ICB10; Immunoglobulin G - biosynthesis; Infusions, Parenteral; Interleukin-5 - metabolism; Life cycle. Host-agent relationship. Pathogenesis; Malaria, Vivax - prevention & control; Maltose-Binding Proteins; Merozoite Surface Protein 1 - chemistry; Merozoite Surface Protein 1 - genetics; Merozoite Surface Protein 1 - immunology; Merozoite surface protein-1; Mice; Mice, Inbred BALB C; Oral immunization; Periplasmic Binding Proteins - chemistry; Periplasmic Binding Proteins - genetics; Periplasmic Binding Proteins - immunology; Plasmodium vivax; Plasmodium vivax - immunology; Protozoa; Protozoan Vaccines - administration & dosage; Protozoan Vaccines - immunology; Recombinant Fusion Proteins - chemistry; Recombinant Fusion Proteins - genetics; Recombinant Fusion Proteins - immunology; Spleen - cytology; Spleen - immunology; Tumor Necrosis Factor-alpha - metabolism; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - immunology
• ISSN: 0014-4894; 1090-2449
• DOI: 10.1016/j.exppara.2010.05.001

The merozoite surface protein-1 (MSP-1) from Plasmodium vivax was evaluated as an oral vaccine candidate by cloning and expressing the interspecies conserved block 10 (ICB10) of the MSP-1 from a Korean isolate in Escherichia coli. The expressed fusion protein contained ICB10 and a maltose-binding protein (MBP), rPv54, has a molecular weight of approximately 54 kDa as determined by SDS–PAGE analysis. IgG against rPv54 was successfully produced in BALB/c mice by oral immunization and sustained for more than 4 months. IgG2b was dominantly produced in both oral and parenteral immunizations. The rPv54 increased the frequency of NK, NKT, CD4+ T, CD8+ T, and B cells in both immunizations. IL-5 and TNF-α were increased in both significantly. In conclusion, rPv54 might be a valuable potential vaccine candidate for the oral and parenteral immunization against vivax malaria.